"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 7 | 10 |
| 1998 | 2 | 4 | 6 |
| 1999 | 2 | 8 | 10 |
| 2000 | 2 | 11 | 13 |
| 2001 | 3 | 11 | 14 |
| 2002 | 8 | 5 | 13 |
| 2003 | 6 | 11 | 17 |
| 2004 | 12 | 14 | 26 |
| 2005 | 13 | 10 | 23 |
| 2006 | 16 | 13 | 29 |
| 2007 | 13 | 15 | 28 |
| 2008 | 23 | 17 | 40 |
| 2009 | 21 | 25 | 46 |
| 2010 | 13 | 20 | 33 |
| 2011 | 25 | 29 | 54 |
| 2012 | 30 | 18 | 48 |
| 2013 | 27 | 30 | 57 |
| 2014 | 17 | 24 | 41 |
| 2015 | 31 | 31 | 62 |
| 2016 | 22 | 34 | 56 |
| 2017 | 30 | 29 | 59 |
| 2018 | 31 | 35 | 66 |
| 2019 | 50 | 32 | 82 |
| 2020 | 43 | 26 | 69 |
| 2021 | 25 | 35 | 60 |
| 2022 | 2 | 27 | 29 |
| 2023 | 0 | 19 | 19 |
| 2024 | 19 | 37 | 56 |
| 2025 | 10 | 4 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients. J Exp Clin Cancer Res. 2025 May 01; 44(1):136.
-
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 05; 23(5):169-191.
-
Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation. PLoS One. 2025; 20(4):e0321736.
-
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025 May; 213(5):590-599.
-
The Impact of the Tumor Microenvironment on the Effect of IL-1ß Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Res Commun. 2025 Apr 01; 5(4):632-646.
-
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons. Clin Transl Sci. 2025 Apr; 18(4):e70227.
-
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients. Oncotarget. 2025 Mar 12; 16:140-162.
-
Novel Histologic Features in Ameloblastoma With RASQ61R Mutation. Am J Surg Pathol. 2025 May 01; 49(5):508-514.
-
Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous Component. Am J Surg Pathol. 2025 May 01; 49(5):439-447.
-
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma. Int J Gynecol Cancer. 2025 Mar; 35(3):101672.